



OFFICE of the DEPUTY PRIME MINISTER  
MINISTRY for HEALTH  
15, PALAZZO CASTELLANIA, MERCHANTS STREET, VALLETTA, MALTA

**DH Circular 91/2019**  
DH 1165/2019

9<sup>th</sup> September 2019

**Attention All:** Consultants  
Medical Officers  
Pharmacists  
Pharmacy Technicians  
Nurses

**Re: Cetuximab 5mg/mL Solution for Infusion**

It is being brought to your attention that as part of Government's policy and commitment to provide improved services and a continuum of care for cancer patients, a new oncology medicine is being added to the current Government Formulary List.

Cetuximab 5mg/mL solution for infusion is now available on the Government Formulary List for in-patient use.

Cetuximab can be prescribed by Consultant Oncologists for metastatic colorectal cancer and squamous cell cancer of the head and neck as per protocol 39 attached (Annex I).

For your attention please.

Dr. Denis Vella Baldacchino  
Chief Medical Officer

## **Cetuximab 5mg/mL Solution for Infusion**

**Prescribed Criteria:** Consultant Oncologist

**In-patient use:**

1. Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer
  - In combination with irinotecan-based chemotherapy
  - First-line in combination with FOLFOX
  - As a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
  
2. Squamous cell cancer of the head and neck
  - In combination with radiation therapy for locally advanced disease,
  - In combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

**Duration of Approval:**

1 year